Nous utilisons des cookies pour vous proposer des contenus et services adaptés. En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies.
Ce site respecte la loi RGPD du 25 mai 2018. Pour en savoir plus, cliquez ici
Fast Facts: Advanced Cutaneous Squamous Cell Carcinoma' is for people who have or may have advanced cutaneous squamous cell carcinoma. It aims to help patients, and people close to them, understand the condition so they can have better discussions with the cancer team. Decisions about treatment and next steps are highly individual. [lire la suite]
A diagnosis of amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease or motor neuron disease) is a progressive neurodegenerative disorder that exerts a notorious life-shortening physical toll. [lire la suite]
Inflammatory bowel disease (IBD) is in fact two long-term conditions – ulcerative colitis or Crohn’s disease – that cause problems in the digestive system. No two patients with IBD have the same experience. How the disease progresses, the type of complications and the response to treatment all differ from person to person. [lire la suite]
The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings.
Immunotherapeutic products, and immune checkpoints inhibitors in particular, are increasingly used in the management of malignancies, both as monotherapies and in combination. Adverse events tend to be mild to moderate, but they can be severe or even life-threatening. Prompt recognition and effective management are vital. [lire la suite]
Although dopaminergic medication is the most effective treatment for patients with Parkinson’s disease (PD), its long-term use is associated with debilitating motor fluctuations. Patients may not spontaneously seek assistance when fluctuations develop, so strategies need to be put in place to identify and alleviate motor dysfunction. [lire la suite]
This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. [lire la suite]